Could New Patent Get OncoSec Medical (ONCS) Over A Dollar?

The penny stock of OncoSec Medical Inc. (OTC: ONCS), a company treating advanced-stage solid tumors, had a rally from mid-December to February 1st gaining 488% . Today, ONCS announced the Commissioner of Patents, Commonwealth of Australia Patent Office, recently granted a new Method of Use patent for the company’s OMS ElectroOncology treatment platform. ONCS stock price is set top open at 0.181: 3.57% above the 50-Day moving average, -46.54% below the 200 Day moving average, and -85.63% below the $1.26 52-week high.

Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.

ONCS Stock Chart

The Company recently filed their 10-Q for the period ended April 30, 2012. Amazingly for an OTC listed penny stock, they reported having $6,569,626 in cash and cash equivalents, total liabilities of just under $3 million, an accumulated deficit of just $4,607,267, no revenues as of yet, but operating expenses for the quarter of just $1,588,849.

There are 87.86 million shares outstanding for OncoSec. However,when scanning the Insiders holding ONCS stock, we found that Avtar Dhillon (see here) and Anthony Maida (see here) both are connected to Stevia First Corp. (STVF) with Dhillon getting the sweet deal of 500,000 stock options at $0.10 on STVF. Both were issued 100,000 stock options on ONCS executable at $0.21 back on April 25th.

Does it mean much about the connection with STVF? Not really.

About OncoSec Medical’s OMS ElectroChemotherapy

OMS ElectroChemotherapy is an investigational therapy being evaluated to reduce the rate of cancer recurrence without quality of life side effects. As a potential adjunct to surgery, this therapeutic approach involves removal (using a scalpel) of the tumor mass, without removal of excess healthy tissue, followed by treatment with OMS ElectroChemotherapy. This approach has been shown to selectively kill cancer cells that may exist in the surrounding tissue, which may result in a reduced rate of recurrence and the potential to complement standard-of-care surgical procedures as an alternative to surgery alone.

More information is available at

To view the SEC filings for ONCS, click here.

Bottom Line: There is very little volume with this penny stock which is one thing traders do not like. In April, ONCS reported some very positive results from their of treatment of recurrent squamous cell carcinoma of the head and neck. If you like long biotech penny stocks, add ONCS to your list.

Here is your opportunity to subscribe to the Most Exclusive Penny Stock newsletter.

Sign up with your email address now & get ready to make BIG PROFITS on Good Penny Stocks

(We are 100% Anti-Spam and will never rent or sell your information)

And Remember to Always:

  • Do Your Own Research.
  • Trade Responsibly.
  • Verify Everything.
  • Move Fast or Get Left Behind.
  • Do not Use Market Orders to Enter a Position, Use Limit Orders.
  • Have a System That fits You.
  • If a Stock Gaps Open, Look for Pullbacks to Enter.
  • Plan a Trade and Trade a Plan.
  • Always Use Stop Loss Orders to Protect Yourself.
  • Positive Attitude / Positive Self- Belief.
  • Keep Penny Stock Trading as Part of a Balanced life.
  • If a Stock Breaks Below Our Alert Price GET OUT. Do not wait.
  • View Trading as a Score in Points and Not In Money:
  • Always Take Your Profits Whenever You Can. Do Not Be Greedy.
  • Work Hard at Learning How to Trade Properly and Keep Working.
  • Do Something to make Someone Else’s Life Better Today.

Last updated by at .

  Recent Penny Stock News